Cargando…
Healthspan Extension through Innovative Genetic Medicines
Genetic medicine has emerged as an innovative class of therapeutics, allowing the development of new and powerful approaches to address a myriad of diseases that were previously untreatable. At the same time, our improved understanding of the mechanisms underlying aging has created novel opportuniti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512234/ https://www.ncbi.nlm.nih.gov/pubmed/36170436 http://dx.doi.org/10.1097/PRS.0000000000009674 |
_version_ | 1784797809157865472 |
---|---|
author | Garcia, Henry Brown, Douglas Scholz, Matthew Lewis, John D. |
author_facet | Garcia, Henry Brown, Douglas Scholz, Matthew Lewis, John D. |
author_sort | Garcia, Henry |
collection | PubMed |
description | Genetic medicine has emerged as an innovative class of therapeutics, allowing the development of new and powerful approaches to address a myriad of diseases that were previously untreatable. At the same time, our improved understanding of the mechanisms underlying aging has created novel opportunities to intervene therapeutically in the aging process itself through the targeting of key pathways driving this process. As individuals age, the onset of a multitude of age-related diseases can significantly impact lifespan. The ultimate goal of their treatment is the maximization of healthy, disease-free years, or healthspan. Here, we discuss a number of promising genetic medicine approaches to target both general and specific mechanisms of age-related disease, and their potential impact on healthspan extension. Essential to this topic is the challenge of nucleic acid delivery, and we discuss the technologies that have been developed to address this challenge in highly promising preclinical and clinical development efforts. In particular, we describe a next-generation delivery technology for healthspan applications called proteo-lipid vehicles. |
format | Online Article Text |
id | pubmed-9512234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95122342022-10-03 Healthspan Extension through Innovative Genetic Medicines Garcia, Henry Brown, Douglas Scholz, Matthew Lewis, John D. Plast Reconstr Surg Science of Aging, Part 3: Original Articles Genetic medicine has emerged as an innovative class of therapeutics, allowing the development of new and powerful approaches to address a myriad of diseases that were previously untreatable. At the same time, our improved understanding of the mechanisms underlying aging has created novel opportunities to intervene therapeutically in the aging process itself through the targeting of key pathways driving this process. As individuals age, the onset of a multitude of age-related diseases can significantly impact lifespan. The ultimate goal of their treatment is the maximization of healthy, disease-free years, or healthspan. Here, we discuss a number of promising genetic medicine approaches to target both general and specific mechanisms of age-related disease, and their potential impact on healthspan extension. Essential to this topic is the challenge of nucleic acid delivery, and we discuss the technologies that have been developed to address this challenge in highly promising preclinical and clinical development efforts. In particular, we describe a next-generation delivery technology for healthspan applications called proteo-lipid vehicles. Lippincott Williams & Wilkins 2021-09-28 2022-10 /pmc/articles/PMC9512234/ /pubmed/36170436 http://dx.doi.org/10.1097/PRS.0000000000009674 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Plastic Surgeons. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Science of Aging, Part 3: Original Articles Garcia, Henry Brown, Douglas Scholz, Matthew Lewis, John D. Healthspan Extension through Innovative Genetic Medicines |
title | Healthspan Extension through Innovative Genetic Medicines |
title_full | Healthspan Extension through Innovative Genetic Medicines |
title_fullStr | Healthspan Extension through Innovative Genetic Medicines |
title_full_unstemmed | Healthspan Extension through Innovative Genetic Medicines |
title_short | Healthspan Extension through Innovative Genetic Medicines |
title_sort | healthspan extension through innovative genetic medicines |
topic | Science of Aging, Part 3: Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512234/ https://www.ncbi.nlm.nih.gov/pubmed/36170436 http://dx.doi.org/10.1097/PRS.0000000000009674 |
work_keys_str_mv | AT garciahenry healthspanextensionthroughinnovativegeneticmedicines AT browndouglas healthspanextensionthroughinnovativegeneticmedicines AT scholzmatthew healthspanextensionthroughinnovativegeneticmedicines AT lewisjohnd healthspanextensionthroughinnovativegeneticmedicines |